BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. Clinical features and management of primary biliary cirrhosis. World J Gastroenterol 2008; 14(21): 3313-3327 [PMID: 18528929 DOI: 10.3748/wjg.14.3313] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, Van Look LA, Johnston GI, Reynolds RM, Strachan MW;  Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34:1139-1144. [PMID: 21478462 DOI: 10.2337/dc10-2229] [Cited by in Crossref: 217] [Cited by in F6Publishing: 202] [Article Influence: 19.7] [Reference Citation Analysis]
2 Liu H, Xu HW, Zhang YZ, Huang Y, Han GQ, Liang TJ, Wei LL, Qin CY, Qin CK. Ursodeoxycholic acid induces apoptosis in hepatocellular carcinoma xenografts in mice. World J Gastroenterol 2015; 21(36): 10367-10374 [PMID: 26420963 DOI: 10.3748/wjg.v21.i36.10367] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
3 Degiorgio D, Crosignani A, Colombo C, Bordo D, Zuin M, Vassallo E, Syrén ML, Coviello DA, Battezzati PM. ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression. J Gastroenterol 2016;51:271-80. [PMID: 26324191 DOI: 10.1007/s00535-015-1110-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
4 Melchor-mendoza YK, Martínez-benítez B, Mina-hawat A, Rodríguez-leal G, Duque X, Moran-villota S. Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability. Annals of Hepatology 2017;16:430-5. [DOI: 10.5604/01.3001.0009.8598] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
5 Antonini T, Samuel D. Indications et résultats de la greffe hépatique (hors carcinome hépatocellulaire et hépatite fulminante). Gastroentérologie Clinique et Biologique 2009;33:44-50. [DOI: 10.1016/j.gcb.2008.11.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
6 Han D, Liu J, Jin E, He W. Liver assessment using Gd-EOB-DTPA-enhanced magnetic resonance imaging in primary biliary cholangitis patients. Jpn J Radiol 2019;37:412-9. [PMID: 30798469 DOI: 10.1007/s11604-019-00822-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Olmez S, Sayar S, Avcioglu U, Tenlik İ, Ozaslan E, Koseoglu HT, Altiparmak E. The relationship between liver histology and noninvasive markers in primary biliary cirrhosis: . European Journal of Gastroenterology & Hepatology 2016;28:773-6. [DOI: 10.1097/meg.0000000000000637] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
8 Trottier J, Białek A, Caron P, Straka RJ, Heathcote J, Milkiewicz P, Barbier O. Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. Dig Liver Dis 2012;44:303-10. [PMID: 22169272 DOI: 10.1016/j.dld.2011.10.025] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 7.1] [Reference Citation Analysis]
9 Dellavance A, Coelho Andrade LE. Immunologic derangement preceding clinical autoimmunity. Lupus. 2014;23:1305-1308. [PMID: 25228734 DOI: 10.1177/0961203314531346] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Czul F, Peyton A, Levy C. Primary biliary cirrhosis: therapeutic advances. Clin Liver Dis. 2013;17:229-242. [PMID: 23540499 DOI: 10.1016/j.cld.2012.12.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
11 Invernizzi P. Geoepidemiology of autoimmune liver diseases. J Autoimmun. 2010;34:J300-J306. [PMID: 20036105 DOI: 10.1016/j.jaut.2009.12.002] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 5.1] [Reference Citation Analysis]
12 Francis H, Meininger CJ. A review of mast cells and liver disease: What have we learned? Dig Liver Dis 2010;42:529-36. [PMID: 20363674 DOI: 10.1016/j.dld.2010.02.016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
13 Huang YQ. Recent advances in diagnosis and treatment of primary biliary cirrhosis. Shijie Huaren Xiaohua Zazhi 2014; 22(16): 2243-2251 [DOI: 10.11569/wcjd.v22.i16.2243] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Baldo DC, Dellavance A, Ferraz MLG, Andrade LEC. Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies. Auto Immun Highlights 2019;10:10. [PMID: 32257066 DOI: 10.1186/s13317-019-0120-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Duan T, Jiang HY, Ling WW, Song B. Noninvasive imaging of hepatic dysfunction: A state-of-the-art review. World J Gastroenterol 2022; 28(16): 1625-1640 [DOI: 10.3748/wjg.v28.i16.1625] [Reference Citation Analysis]
16 Nilsson H, Blomqvist L, Douglas L, Nordell A, Jonas E. Assessment of liver function in primary biliary cirrhosis using Gd-EOB-DTPA-enhanced liver MRI. HPB (Oxford). 2010;12:567-576. [PMID: 20887325 DOI: 10.1111/j.1477-2574.2010.00223.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
17 Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today. 2012;17:988-997. [PMID: 22652341 DOI: 10.1016/j.drudis.2012.05.012] [Cited by in Crossref: 175] [Cited by in F6Publishing: 160] [Article Influence: 17.5] [Reference Citation Analysis]
18 Ngu JH, Gearry RB, Wright AJ, Stedman CAM. Low incidence and prevalence of primary biliary cirrhosis in Canterbury, New Zealand: a population-based study. Hepatol Int 2012;6:796-800. [DOI: 10.1007/s12072-011-9329-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
19 Akamatsu N, Sugawara Y. Primary biliary cirrhosis and liver transplantation. Intractable Rare Dis Res 2012;1:66-80. [PMID: 25343075 DOI: 10.5582/irdr.2012.v1.2.66] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Lüth S, Weiler-Normann C, Schramm C, Lohse AW. [Autoimmune liver diseases]. Internist (Berl). 2009;50:310-317. [PMID: 19225747 DOI: 10.1007/s00108-008-2254-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
21 Nevens F. PBC-transplantation and disease recurrence. Best Practice & Research Clinical Gastroenterology 2018;34-35:107-11. [DOI: 10.1016/j.bpg.2018.09.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Fernández MIC, Hernández DR, Cabrera Eugenio DE, Palanca W, Guridi ZD, González Fabián L. Diagnosis and Treatment of Autoimmune Liver Diseases in a Tertiary Referral Center in Cuba. Curr Ther Res Clin Exp 2017;85:8-14. [PMID: 29158853 DOI: 10.1016/j.curtheres.2017.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
23 Garg D, Nagar A, Philips S, Takahashi N, Prasad SR, Shanbhogue AK, Sahani DV. Immunological diseases of the pancreatico-hepatobiliary system: update on etiopathogenesis and cross-sectional imaging findings. Abdom Imaging 2012;37:261-74. [PMID: 21597892 DOI: 10.1007/s00261-011-9759-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
24 Stojakovic T, Claudel T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Sourij H, Stauber RE, Winkler K, März W. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis. 2010;209:178-183. [PMID: 19782361 DOI: 10.1016/j.atherosclerosis.2009.08.052] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
25 Minz RW, Kaur N, Anand S, Aggarwal R, Saikia B, Das A, Chawla YK. Complete spectrum of AMA-M2 positive liver disease in north India. Hepatol Int 2012;6:790-5. [PMID: 26201527 DOI: 10.1007/s12072-011-9326-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Kremer AE, Rust C, Eichhorn P, Beuers U, Holdenrieder S. Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers. Expert Rev Mol Diagn 2009;9:139-56. [PMID: 19298138 DOI: 10.1586/14737159.9.2.139] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]